

BASSAM I. MATTAR, MD, FACP

CURRICULUM VITAE

PERSONAL DATA

Name: Bassam Ibrahim Mattar
Current Academic Rank: Clinical Associate Professor
Department(s): Internal Medicine

Office Address, Phone, Fax

Cancer Center of Kansas, P.A.
818 North Emporia, Suite 403
Wichita, Kansas 67214
Ph: 316-262-4467 – Fax: 316-262-0706

PROFESSIONAL DEVELOPMENT

Staff Physician

Cancer Center of Kansas, P.A. 07/01/1999 - present

Physician Partner

Cancer Center of Kansas, P.A. 2001 - present

Undergraduate and Graduate Education

<u>Years</u>	<u>Degree</u>	<u>Institution</u>
1986-1993	M.D.	St. Joseph University, Beirut, Lebanon

Postgraduate Education

<u>Years</u>	<u>Area of Study</u>	<u>Institution</u>
1994-1994	Internship Internal Medicine	Our Lady of Mercy Medical Center New York
1994-1996	Residency in Internal Medicine	University of Kansas School of Medicine Wichita
1996-1999	Fellow, Hem/Onc BMT	University of Alabama Birmingham, Alabama

Continuing Education

September – November, 2020: HMX Pro program (Harvard Medical School online learning platform) – Certificate of Achievement in Immunology - Immuno-oncology

March 2021: HMX Pro program (Harvard Medical School online learning platform) – Certificate of Completion in State-of-the-Art in Oncology Therapeutics Development event

Academic and Professional Appointments and Activities:

<u>Month/Year</u>	<u>Position</u>	<u>Institution</u>
7/1999 -	Clinical Privileges	Ascension Via Christi
7/1999 -	Clinical Privileges	Wesley Medical Center
11/1999 -	Clinical Privileges	Veteran’s Hospital – Wichita
1999 -	Clinical Asst. Professor	University of Kansas School of Medicine
2000 -	Clinical Privileges	Kingman Community Hospital
2000 - Board (IRB)	Institutional Review	Wesley Regional Medical Center
2000 -	IRB	Veterans Administration
2000 -	IRB	Ascension Via Christi
2001 -	Clinical Privileges	Newton Medical Center – Newton, KS
11/2005 -	Director of the Kansas Blood and Marrow Program	Ascension Via Christi (in collaboration with Cancer Center of Kansas and American Red Cross)

Professional Registration/Licensure:

<u>Year</u>	<u>State</u>
1998-Present	Kansas
Inactive	Alabama
Inactive	Iowa

Professional Certification(s):

<u>Date</u>	<u>Status</u>	<u>Board</u>
08/1996	Current	American Board of Internal Medicine
11/1999	Current	Subspecialty (ABIM) Medical Oncology
11/2000	Current	Subspecialty (ABIM) Hematology

Professional Societies and Affiliations:

<u>Year</u>	<u>Organization (including offices held)</u>
2021-2023	Midwest Stem Cell Therapy Center (Advisory Board), <i>Representing Ascension Via Christi Health</i>
2020-	International Lebanese Medical Association, USA Chapter (Advisory Board)
1999	National Cancer Institute (NCI)
1999-	Wichita Community Clinical Oncology Program (WCCOP)
1999-	Southwest Oncology Group (SWOG)
2001-	Leukemia Society of America (Kansas Chapter)
2001-	Victory in the Valley (Board of Directors) Local Cancer Support Group
2006-	US TOO International, Inc., Wichita, KS Chapter (Honorary Member Board of Directors) Prostate Cancer Group

Professional Societies and Affiliations: (continued)

2003- American College of Physicians Fellow
2001- American Cancer Society
1999- American Society of Hematology
1999- American Society of Clinical Oncology
1999- American Society for Blood and Marrow Transplantation
1999- Kansas Society of Clinical Oncology

Honors and Awards:

<u>Year</u>	<u>Award</u>
2016	Wichita Business Journal's Health Care Hero Award
2011	Platinum Award (≥ 25 patients Total Accruals in WCCOP NCI Treatment and Cancer Control Clinical Trials)
2006	Victory in the Valley (Local Cancer Support Group) Medal of Honor Award for Encouragement in support of patients
2005	Via Christi Regional Medical Center St. Luke Award Physician Recognition Award for the Core Value of Community (Promoting a sense of family and unity among those being served and those providing service)
2001	American Cancer Society Prevention of Cancer Community Service Award

TEACHING ACTIVITIES

Areas of teaching interest: Lymphoma, hematologic malignancies and stem cell transplantation

1. Instruction:

2006-2007	7 Internal Medicine 1 VCSF Family Medicine
2005-2006	3 Internal Medicine 1 Cancellation
2004-2005	3 Internal Medicine 1 removed for backup duty Med Service
2003-2004	4 Internal Medicine 1 VCSF Family Medicine 2 Cancelled; 1 removed for backup Med Service
2002-2003	3 Internal Medicine 1 Cancellation
2001-2002	4 Internal Medicine 6 VCSF 6 residents were ½ month rotations
2000-2001	4 Internal Medicine 1 VCSF Family Medicine

2. Oral Presentation to professional audiences

- 8/1999 Updates on Pathogenesis and Treatment/Via Christi St. Joseph
- 9/1999 Updates on Pathogenesis and Treatment/Riverside Hospital
- 9/1999 Bone Marrow Transplantation/Riverside Hospital
- 9/1999 Grand Rounds Breast and Lung Cancer/Riverside Hospital
- 1999- Grand Rounds Case Presentation for CME /Wesley Medical Center
- 1999- Grand Rounds Case Presentation for CME /Via Christi Regional Med Center
- 2000- Physicians Outreach Program /Via Christi Regional Medical Center
- 2000- Morning Case Conference /Wesley Medical Center
- 2001- Bleeding Disorders Grand Rounds/Via Christi Regional Med Center
- 2001- Heparin Induced Thrombocytopenia/Via Christi Regional Med Center
- 2002- Heparin Induced Thrombocytopenia/Wesley Medical Center
- 2001- Heparin Induced Thrombocytopenia/Kingman Hospital
- 2005- Hemochromatosis/Resident Presentations /Via Christi St. Joseph
- 2005- Renal Cancer/Resident Presentations/Via Christi St Joseph
- 2005- Multiple Myeloma/Resident Presentations/Via Christi St. Joseph
- 2005- Colon Cancer/Resident Presentations/Via Christi St. Joseph
- 2021- CAR-T Cell Therapy/Tulane University

3. Non Didactic

- 2005- Weekly meetings as Director of Kansas Blood and Marrow Transplantation program at Ascension Via Christi, Kansas.. Meetings include Oncology physicians; VCRMC Lab Director; VCRMC Medical Director, Oncology BMT nursing staff and the American Red Cross.
- 2021- As the Director of the Kansas Blood and Marrow Program at Ascension Via Christi, mentored and advised the Ascension Tennessee medical group with the opening of a new CAR-T Cell and blood and marrow program

4. Clinical

80 hours of patient care a week. Interaction with residents thru consultations and rotating physician. Evaluates cancer patients with all different types of cancer at the office and hospital consults. Special interest in Bone Marrow Transplantation; Leukemia; Breast and prostate cancers.

5. Master's Thesis and PhD. Dissertations directed

Supervision of Postdoctoral fellows

6. Development of Educational Materials

Draws on experience of senior staff at Cancer Center of Kansas. References the following: National Cancer Institute, UP TO DATE; Bone Marrow Transplantation; American Society of Hematology, American Society of Clinical Oncology and various other oncology resources. American College of Physicians Medical Knowledge Self-Assessment Program MKSAP.

RESEARCH and SCHOLARLY ACTIVITIES:

Research in the areas of Lymphoma, hematologic malignancies and stem cell transplantation. Sub-investigator with Wichita CCOP, which is sponsored and funded by the National Cancer Institute, the primary cancer research arm of the National Institute of Health.

Scientific papers submitted but not yet accepted:

1. Bryce AL, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K, Wender DB, Soori G, Perez EA, Jett JR: Phase II trial of oral topotecan and intravenous carboplatin with G-CSF (filgrastim) support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study (N0027). (submitted to *Am J Clin Oncol* January, 2009)
2. Mattar B, Carabasi MH, Tilden AB, Salzman D, Martin B, Kunkel L, Vaughan WP: Improved Outcome in Recipients of HLA Identical T-Cell Depleted Allogeneic Peripheral Blood Stem Cell Transplants Containing High Dose of Stem Cells. Department of Medicine, Research Development Group. Submitted.
3. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich D, Rowland KM, Mattar BI, Loprinzi CL: A placebo-controlled, double blind trial of Infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). (submitted April 2009)
4. Armatruda T, Kottschade LA, Suman VJ, Kaur JS, Pitot HC, Croghan GA, McWilliams RR, Creagan ET, Mattar BI, Nikcevich D, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN: A Phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable Stage IV melanoma – A North Central Cancer Treatment Group Study, N057E. (submitted November 2009)
5. Roy V, Apsey H, Allred JB, Pockaj BA, Northfelt D, Nikcevich D, Mattar, BI, Perez EA. A Phase II trial of docetaxel and carboplatin administered every two weeks as preoperative therapy for stage II or III breast cancer: NCCTG Study N0338. (submitted to *Annals of Onc.*, October 2011)
6. Alberts SR, Soori GS, Shi Q, Wigle D, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Wu TT, Yoon H, Drevyanko TF, Ko SJ, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP: Randomized Phase II Trial of Extended Versus Standard Neoadjuvant Therapy for Esophageal Cancer, NCCTG Clinical Trial N0849.

Published abstracts:

1. Mattar B: Gastrointestinal Lymphoma. Medical Diploma Thesis, 1993 February.
2. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III Randomized Trial of Cisplatin Plus Placebo Compared with Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer. An Eastern Cooperative Oncology Group Study. *J Clin Oncol.* 2005 Dec 1;23(34):8646-8654.
3. Giordano KF, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K, Wender DB, Mailliard J, Perez EA, Jett JR: Phase II Trial of Oral Topotecan and Intravenous Carboplatin with G-CSF (Filgrastim) Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: A North Central Cancer Treatment Group Study. *J Thorac Onc.* 2006;1(3):211-7.
4. El-Osta HE, Yammine YS, Chehab BM, Fields AS, Moore DF, Mattar BI: Unexplained Hemopericardium as Presenting Feature of Primary Cardiac Angiosarcoma: A Case Report and a Review of the Diagnostic Dilemma. *J Thorac Oncol.* 2008 Jul;3(7):800-802.
5. Apsy HA, Roy V, Pockaj BA, Northfelt DW, Sticca RP, Nikcevich D, Mattar BI, Fitch TR, Perez EA: Surgical Practice Patterns Following NCCTG N0338 Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II and Stage III Breast Cancer. *J Clin Oncol.* 2009;27(15s): #623.
6. Wolf SL, Qin R, Barton DL, Sloan JA, Liu H, Aaronson N, Satele D, Green NB, Mattar BI, Loprinzi CL: Relationship of Sensory Symptoms and Motor Function in Patients with Chemotherapy Induced Peripheral Neuropathy (CIPN) Utilizing the EORTC QLQ CIPN20: NCCTG Study N06CA. *J Clin Oncol.* 2009;27(15s): #9587.
7. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD, Kugler JW, Rowland KM, Loprinzi CL: A Randomized Controlled Trial Evaluating a Topical Treatment for Chemotherapy-Induced Peripheral Neuropathy, NCCTG Trial N06CA. *J Clin Oncol.* 2009;27(15s): #9531.
8. Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C, Duane S, Mattar B, Liu H, Atherton PJ, Christensen B, Loprinzi CL: Pilot Study of Panax Quinquefolius (American Ginseng) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Dose-Finding Evaluation: NCCTG Trial N03CA. *Support Care Cancer.* 2010 Feb;18(2):179-187. Epub 2009 May 6.
9. Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women with Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy. *Breast.* 2010 Apr;19(2):92-96. Epub 2010 Jan 15.
10. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL: Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash? Results of a Placebo-Controlled Trial From the North Central Cancer Treatment Group (N05C4). *Oncologist.* 2010;15(9):1016-1022. Epub 2010 Aug 26.

11. Jatoui A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, Mattar BI, Loprinzi CL: A Placebo-Controlled, Double-Blind Trial of Infliximab for Cancer-Associated Weight Loss in Elderly and/or Poor Performance Non-Small Cell Lung Cancer Patients (N01C9). *Lung Cancer*. 2010 May;68(2):234-239. Epub 2009 Aug 8.
12. Bryce AH, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K Jr, Wender DB, Soori G, Perez EA, Jett JR: Phase II Trial of Oral Topotecan and Intravenous Carboplatin with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: A North Central Cancer Treatment Group Study. *Am J Clin Oncol*. 2010 Aug;33(4):353-357.
13. Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, Rowland KM Jr, Zon RT, Lelindqwister NA, Nagargoje GG, Morgenthaler TI, Sloan JA, Loprinzi CL: The Use of Valeriana Officinalis (Valerian) in Improving Sleep in Patients Who are Undergoing Treatment for Cancer: A Phase Iii Randomized, Placebo-Controlled, Double-Blind Study (NCCTG Trial, N01C5). *J Support Oncol*. 2011 Jan-Feb;9(1):24-31
14. Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN: A Phase II Trial of nab-Paclitaxel (ABI-007) and Carboplatin in Patients with Unresectable Stage IV Melanoma: a North Central Cancer Treatment Group Study, N057E(1). *Cancer*. 2011 Apr 15;117(8):1704-1710. Epub 2010 Nov 8.
15. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr, Riepl M, Christensen B, Loprinzi CL: A Double-Blind, Placebo-Controlled Trial of a Topical Treatment for Chemotherapy-Induced Peripheral Neuropathy: NCCTG Trial N06CA. *Support Care Cancer*. 2011 Jun;19(6):833-841. Epub 2010 May 25.
16. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL: The Relationship Between Numbness, Tingling, and Shooting/Burning Pain in Patients with Chemotherapy-Induced Peripheral Neuropathy (CIPN) as Measured by the EORTC QLQ-CIPN20 Instrument, N06CA. *Support Care Cancer*. 2012 Mar;20(3):625-632. Epub 2011 Apr 12.
17. Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B, Perez EA: A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer: NCCTG Study N0338. *Am J Clin Oncol*. 2012 Aug 2. Epub ahead of print.
18. Chalhoub E, Mattar BI, Shaheen W, Schulz TK: Cardiac Angiosarcoma Presenting with Tamponade. *Intern Med*. 2012;51(20):2905-2907. Epub 2012 Oct 15.
19. Sanchorawala V, Hoering A, Seldin D, Finn K, Fennessey S, Sexton R, Mattar B, Safah H, Holmberg L, Dean R, Orlowski R, Barlogie B: Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for AL Amyloidosis or High-Risk Myeloma: Analysis of SWOG Trial S0115. *Bone Marrow Trans*. 2013 July 15. Epub ahead of print.
20. Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA: A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and

- Concurrent Thoracic Radiation Therapy for Non-small-cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321. *J Thorac Oncol.* 2015 Jan; 10(1):172-80.
21. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF Jr, Nikcevich D, Loprinzi CL: A Randomized Comparison of Once Weekly Epoetin Alfa to Extended Schedule Epoetin or Darbepoetin in Chemotherapy-Associated Anemia. *Am J Hematol*, 2015 Jul 6. Epub 2015 Aug 14.
 22. Yao JC, Guthrie K, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte NK, McWilliams RR, Wolin EM, Mattar BI, McDonough S, Chen HX, Blanke, CD, Hochster HS: SWOG S0518: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha-2b Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced Poor Prognosis Carcinoid Patients (NCT00569127). *J Clin Oncol* 33, 2015 (suppl; abstr 4004).
 23. Reddy PS, Rahal AK, Kallail KJ, Moore DF, Truong PV, Mattar BI, Cannon MW, Nababout NH, Page SJ, Truong QV, Dakhil C, Deutsch JM, Dakhil SR: The Application of Next-Generation Sequencing in the Community Clinical Oncology Setting. *J Clin Oncol.* 34, 2016 (suppl; abstr e23145)
 24. Yao JC, Guthrie K, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte NK, McWilliams RR, Wolin EM, Mattar BI, McDonough S, Chen HX, Blanke, CD, Hochster HS: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. *The Journal of Clinical Pharmacology.* 2017 Apr 6;JCO2016704072. Epub ahead of print)
 25. Cheung, Eric M, et al. “Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.” *The Journal of Clinical Pharmacology*, vol. 57, no. 11, 31 May 2017, pp. 1400–1408., doi:10.1002/jcph.942.
 26. Barton, D L, et al. “Systemic and Local Effects of Vaginal Dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).” *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer., U.S. National Library of Medicine.* 29164377. 21 Nov 2017
 27. Shepherd, L, et al. “Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).” *Breast Cancer Research and Treatment.* 2018 February.
 28. Litovich, Carlos, et al. “Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome.” *Blood Advances.* June 2021.
 29. Yoon HH, Ou FS, Soori GS, et al. “Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial” *Eur J Cancer.* June 2021

30. Herrera, Alex F et al. “Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.” *Blood advances* vol. 5,18. Sept 28, 2021

Poster presentations at national and international meetings:

1. Mattar B, Carabasi MH, Tilden AB, Salzman D, Martin B, Kunkel L, Vaughan WP: Improved Outcome in BMT using T-Cell Depleted High Dose Peripheral Blood Stem Cells Product. Abstract ASH, 1997. Poster presented during Medical Research Symposium at University of Alabama at Birmingham.
2. Miller DM, Jones D, Partia ML, Urish M, Ebbinghaus S, Mattar B, Redden D: Effective IL-2 Based Adjuvant Therapy for High Risk Malignant Melanoma Patients. Am Soc Clin Oncol, 1997. Poster presentation.
3. Carabasi MH, Mattar B, Tilden AB, Bucy RP, Salzman D, Lucas KG, Sig AP, McMennis J, Vaughan WP: Impact of CD34+Cell Selection on GVHD in Recipients of Stem Cell Transplants from HLA-Identical Siblings. Bone Marrow Transplant Service University of Alabama at Birmingham, Birmingham, AL. Abstract.
4. Miller DM, Jones D, Partia ML, Urist M, Ebbinghaus S, Mattar B, Redden D: Effective Interleukin-2 Based Adjuvant Therapy for High Risk Malignant Melanoma Patients. Proceedings of ASCO 1998;17:507a,1954.
5. Mattar B. Effect of CD-34 Peripheral Blood Progenitor Cell Dose on Hematopoietic Recovery, 1999.
6. Burtness BA, Li Y, Flood W, Mattar BI, Forastiere AA: Phase III Trial Comparing Cisplatin (c) + Placebo (P) to C+ Anti-Epidermal Growth Factor Antibody (EGF-R) C225 in Patients with Metastatic/Recurrent Head and Neck Cancer (HNC). Proceedings of ASCO 2002;21:901.
7. Jett JR, Bernath AM, Hillman SL, Krook JE, Mattar BI, Lair BS, Carroll TJ: Oral Topotecan and Paclitaxel with G-CSF Support in Patients with Untreated Extensive Stage Small Cell (EDSCLC): a Phase II Trial of the NCCTG. Proceedings of ASCO 2002;21:1301: 326a. General Poster.
8. Jatoi A, Dakhil SR, Burch PA, Mattar BI, Sloan JA, Fitch TR, Novotny PJ, Camoriano JK, Young CY, Rowland KM, Quevedo F, Tan WW. A phase II trial of green tea for androgen-independent prostate cancer. A North Central Cancer Treatment Group (NCCTG) trial. Pro Am Soc Clin Onc 2002.
9. McGuirk JP, Williams CB, Barnhart CS, Mattar B, Johnson D, Belt RJ, Abyhankar S: Reduced-Intensity Conditioning Stem Cell Transplant (RIC-SCT) with Fludarabine/Busulfan/ATG for Hematopoietic Malignancies. Poster Presentation Tandem Bone Marrow Transplantation Meetings. Keystone, CO. January 30-February 3, 2003.
10. Oral topotecan and intravenous carboplatin with G-CSF support in previously treated patients with extensive stage small cell lung cancer: A phase II trial of the North Central Cancer Treatment Group.Jett J, Mattar BI, Hillman SL, Kugler J, Michalak JC, Adjei AA, Johnson EJ. Clin. Oncol. 2004-07-15

11. Oral topotecan and intravenous carboplatin with G-CSF support in previously treated patients with extensive stage small cell lung cancer: A phase II trial of the North Central Cancer Treatment Group. Jett J, Mattar BI, Hillman SL, Kugler J, Michalak JC, Adjei AA, Johnson EJ. Clin. Oncol. 2004-07-15
12. Vivek R, Pockaj BA, Northfelt DW, Allred JB, Liu H, Nikcevich DA, Mattar BI, Perez EA: N0338 Phase II Trial of Decetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer. Proceedings of ASCO 2008;26:#563
13. Hines S, Sloan JA, Atherton P, Perez E, Dakhil S, Johnson D, Reddy P, Dalton R, Mattar B, Loprinzi C. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. San Antonio Breast Cancer Symposium 2009; 2103 (N02C1).
14. Goetz MP, Foster NR, Meyers JP, Steen PD, Visscher DW, Yoon HH, Pillai R, Prow DM, Reynolds CM, Marchello BT, Mowat RB, Mattar BI, Erlichman C. Use of Gene Expression Profiling to Identify Responsive Patients Treated with Carboplatin (Carb), Paclitaxel (Pac), and Everolimus as First-Line Treatment for Cancer of Unknown Primary (CUP): NCCTG N0871 (Alliance). ASCO Annual Meeting, May 31-June 4, 2013, Chicago, IL. Poster Presentation.
15. Gene Expression Profiling Identifies Responsive Patients with Cancer of Unknown Primary Treated with Carboplatin, Paclitaxel, and Everolimus: NCCTG N0871 (Alliance). Yoon, H. H., Foster, N. R., Meyers, J. P., Steen, P. D., Visscher, D. W., Pillai, R., Prow, D. M., Reynolds, C. M., Marchello, B. T., Mowat, R. B., Mattar, B. I., Erlichman, C., Goetz, M. P. Ann. Oncol. 2015 Nov 19
16. Gene Expression Profiling Identifies Responsive Patients with Cancer of Unknown Primary Treated with Carboplatin, Paclitaxel, and Everolimus: NCCTG N0871 (Alliance). Yoon, H. H., Foster, N. R., Meyers, J. P., Steen, P. D., Visscher, D. W., Pillai, R., Prow, D. M., Reynolds, C. M., Marchello, B. T., Mowat, R. B., Mattar, B. I., Erlichman, C., Goetz, M. P. Ann. Oncol. 2015 Nov 19
17. Gene Expression Profiling Identifies Responsive Patients with Cancer of Unknown Primary Treated with Carboplatin, Paclitaxel, and Everolimus: NCCTG N0871 (Alliance). Yoon, H. H., Foster, N. R., Meyers, J. P., Steen, P. D., Visscher, D. W., Pillai, R., Prow, D. M., Reynolds, C. M., Marchello, B. T., Mowat, R. B., Mattar, B. I., Erlichman, C., Goetz, M. P. Ann. Oncol. 2015 Nov 19
18. Young, Derek, et al. "A Retrospective Analysis Comparing Efficacy of Filgastrim-sndz Versus Filgastrim for Autologous, Peripheral Stem Cell Mobilization in Patients With Multiple Myeloma and Lymphoma." Abstract #225533, submitted at ASCO Annual Mtg. 1-5 May 2018
19. Choucair K., Mattar B, Truong Q, Koeneke T, Truong P, Dakhil C, Cannon M, Page S, Deutsch J, Carlson E, Moore D, Nabbout N, Kallail KJ, Dakhil SR, Reddy PS. "Liquid biopsy: a promising gateway to implementing precision medicine and clinical trials; a community-based oncology practice experience." Submitted at 2020 ASCO Annual Meeting.

20. Bachier, Carlos, et al. “Outcomes of Treatment with the CAR T Cell Therapy Lisocabtagene Maraleucel in the Nonuniversity Setting: Initial Results from the OUTREACH Study.” 2020 Nov 2. Submitted at American Society of Hematology 2020 Annual Meeting.
21. Bachier, Carlos, et al. “Outcomes of Treatment With the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results From the OUTREACH Study in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL).” 2021 Feb 8-12. Submitted at 2021 TCT Annual Meeting.
22. Bachier, Carlos, et al. “Outcomes of Treatment With the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results From the OUTREACH Study in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL).” 2021 Mar 14-17. Submitted at 2021 Blood and Marrow Transplantation (EBMT) Meeting.
23. Bachier, Carlos, et al. “CAR-T Abstract: "OUTREACH: Safety & Efficacy Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting.” 2021 June 4-8. Submitted at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
24. Bachier, Carlos, et. al. “OUTREACH: Safety & Efficacy Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting.” Submitted at 2021 June European Hematology Association – 26th Congress.
25. Mattar, B., et al. “Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)”. 2021 October. Submitted at 2021 American Society of Hematology (ASH) Meeting.

Updated: 10/21/2021